These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 33016924)

  • 21. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
    Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.
    Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA
    J Clin Invest; 2019 Nov; 129(11):4992-5004. PubMed ID: 31609250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of somatic mutations in human gastrointestinal cancers.
    Tran E; Ahmadzadeh M; Lu YC; Gros A; Turcotte S; Robbins PF; Gartner JJ; Zheng Z; Li YF; Ray S; Wunderlich JR; Somerville RP; Rosenberg SA
    Science; 2015 Dec; 350(6266):1387-90. PubMed ID: 26516200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Not Available].
    Depil S; Bonaventura P; Alcazer V; Tonon L
    Bull Cancer; 2018 Dec; 105 Suppl 1():S113-S120. PubMed ID: 30595192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.
    Fotin-Mleczek M; Zanzinger K; Heidenreich R; Lorenz C; Thess A; Duchardt KM; Kallen KJ
    J Gene Med; 2012 Jun; 14(6):428-39. PubMed ID: 22262664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing neoantigen-targeted T cell-based treatments for solid tumors.
    Yamamoto TN; Kishton RJ; Restifo NP
    Nat Med; 2019 Oct; 25(10):1488-1499. PubMed ID: 31591590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized cancer vaccines: Targeting the cancer mutanome.
    Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
    Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads.
    Lussier DM; Alspach E; Ward JP; Miceli AP; Runci D; White JM; Mpoy C; Arthur CD; Kohlmiller HN; Jacks T; Artyomov MN; Rogers BE; Schreiber RD
    Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    Ott PA; Dotti G; Yee C; Goff SL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination.
    Sun X; Zeng L; Huang Y
    J Gene Med; 2019 Jul; 21(7):e3089. PubMed ID: 30958606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cancer Vaccine Focused on Neoantigens].
    Shindo Y; Hazama S; Nagano H
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1367-1371. PubMed ID: 31530772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
    Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
    Front Immunol; 2021; 12():644637. PubMed ID: 33927717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteogenomic Platform for Identification of Tumor Specific Antigens.
    Faktor J; Hernychová L; Vojtěšek B; Hupp T
    Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.